Research programme: anti-alpha folate receptor monoclonal antibody - Dompe

Drug Profile

Research programme: anti-alpha folate receptor monoclonal antibody - Dompe

Alternative Names: AFRA; Anti-α-FR Mab; FabOvar

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dompe Farmaceutici
  • Developer Advanced Accelerator Applications; Dompe Farmaceutici
  • Class Monoclonal antibodies
  • Mechanism of Action Folate receptor 1 antagonists; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer

Most Recent Events

  • 01 Feb 2018 Advanced Accelerator Applications has been acquired by Novartis
  • 29 Jun 2016 Discontinued - Preclinical for Ovarian cancer in Italy (Parenteral)
  • 01 Aug 2011 FabOvar licensed to Advanced Accelerator Applications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top